Partnerships are the best way to achieve a critical mass for success and to sustain a long-term investment, because Curative research is long-term, costly, and has extraordinarily high risks and no one group will be able to solve this problem alone.

Qura Therapeutics was formed in partnership with University of North Carolina at Chapel Hill and GSK and is focused on finding a cure for HIV. This incredibly unique public-private partnership is redefining the traditional way of conducting research and is creating a new model to seek the breakthroughs needed to tackle an extraordinarily challenging global health issue. Worldwide 37 million are living with HIV. While highly active antiretroviral therapy (HAART) has offered the opportunity for most but not all infected individuals to achieve relatively normal life expectancies, there is, as yet no cure. Thus, the search for a cure for HIV infection remains a top priority of health organizations worldwide.

Qura Therapeutics is providing financial and material support to the UNC HIV Cure Center to discover a cure for HIV and Qura Therapeutics will also assist in the development of therapies that emerge from the research.